IL-2 has also been studied as a complementary therapy in CVID, resulting in increased T cell responses to mitogens and soluble antigens in the absence of changes in CD4 count and NK cell frequency (64) while iNKT cell frequency was not evaluated. This evidence concerns the gene CD4 and common variable immunodeficiency.